综述 Review

尿激酶型纤溶酶原激活物受体及可溶性尿激酶型 纤溶酶原激活物受体与炎症相关的研究进展

Published at: 2014年第34卷第4期

刘揆亮 1 , 吴静 1
1 首都医科大学附属北京世纪坛医院消化内科,北京 100038
通讯作者 静 吴 Email: wujing36@163.com
DOI: 10.3978/j.issn.2095-6959.10.3978/j.issn.2095-6959.2014.04.021
基金:

摘要

尿激酶型纤溶酶原激活物受体(urokinase plasminogen activator receptor,uPAR)与尿激酶型纤溶酶原 激活物(urokinase plasminogen activator,uPA)同为纤溶酶原激活系统的主要成员,是一种协调多种 信号转导途径的多功能分子,可溶性尿激酶型纤溶酶原激活物受体(soluble urokinase plasminogen activator receptor,suPAR)是其可溶形式。除凝血-纤溶以外,uPAR参与了肿瘤侵袭及炎症等多种 疾病过程,而suPAR可能是一种良好的炎性标志物。本文就uPAR及suPAR在炎症中的作用进行简要 综述。


Recent advances of urokinase plasminogen activator receptor and soluble urokinase plasminogen activator receptor in inflammation

Abstract

Urokinase plasminogen activator receptor (uPAR) and urokinase plasminogen activator (uPA) are both members of plasminogen activator system. uPAR is a multifunctional molecule in orchestrating multiple signal processes, and suPAR is the soluble form of uPAR. Besides coagulation and fibrinolysis, uPAR is also involved in other pathological processes, such as cancer and inflammation. suPAR is suggested as a potent inflammatory marker. We briefly reviewed recent advances about the role of uPAR and suPAR in inflammation in this article.


comments powered by Disqus

全文

引用

引用本文: 揆亮 刘, 静 吴. 尿激酶型纤溶酶原激活物受体及可溶性尿激酶型 纤溶酶原激活物受体与炎症相关的研究进展 [J]. 临床与病理杂志, 2014, 34(4): 425-430.
Cite this article as: LIU Kuiliang, WU Jing . Recent advances of urokinase plasminogen activator receptor and soluble urokinase plasminogen activator receptor in inflammation [J]. Journal of Clinical and Pathological Research, 2014, 34(4): 425-430.